Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs. This story matters for Finance & Markets readers tracking fund. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →